Vitality Watch

Dossier pubmed trial early 22-oct-2026
Small or early-phase human trial or pilot study

Time restricted eating through self-regulatory behaviors for metabolic and cognitive health in mild cognitive impairment: Feasibility and acceptability findings from the TEMPO trial.

Key claim: A 16-18-hour time-restricted eating protocol practiced 2-3 days per week is feasible and well accepted among older adults with mild cognitive impairment and metabolic risk factors.

Abstract

BackgroundMild cognitive impairment (MCI) and Alzheimer’s disease and related dementias (ADRD) occur at 1.5-2-fold higher rates among adults with obesity or metabolic syndrome. Time restricted eating (TRE) represents a portable and potentially effective strategy to enhance metabolic function and reduce ADRD risk.ObjectiveTo assess the feasibility and acceptability of TRE among older adults with MCI and metabolic risk.MethodsWe assessed a 16-18-h TRE protocol, implemented 2-3 days per week, among older adults (65-85 years of age) with MCI (proposed n = 40) and metabolic risk over 12-weeks. Feasibility was assessed by recruitment and completion of trial activities, while Acceptability was assessed using psychometric self-report. Cognitive function was assessed using a standard neuropsychological test battery, including tests of Executive Function/Processing Speed (Trail Making, Stroop, Controlled Oral Word Association Test, Animal Naming, Digit Span, and Digit Symbol Substitution Tests), Learning/Memory (Hopkins Verbal Learning Test-Revised and Benton Visual Memory Test-Revised. We also examined treatment- and state-dependent changes in metabolic and inflammatory biomarkers, including multiple ketone metabolites and pro-inflammatory cytokines, among others.ResultsFrom 9/28/23 until 3/25/25, thirty-three individuals (83% of target goal [n = 40]) were recruited. Enrolled participants completed all treatment sessions and assessments (100%) and self-reported Acceptability was high. Modification of study recruitment practices and inclusion criteria allowed for an increased screening-to-recruitment ratios over the course of the trial, rising from 1.3% to 11.1%, while still resulting in appropriate recruitment of individuals with MCI.ConclusionsTRE is a feasible and acceptable intervention among older adults with metabolic risk factors.

Why this matters

[human-observational] TEMPO adds population-specific feasibility and acceptability findings for intermittent TRE in older adults with mild cognitive impairment and metabolic risk factors; randomization is not specified in the supplied finding. [human-observational] These implementation findings do not establish improvements in cognitive outcomes or metabolic surrogates, prevention of dementia, or longer lifespan, keeping acceptability distinct from the benefits often attributed to fasting.

Source

Link

Briefing card

Time restricted eating through self-regulatory behaviors for metabolic and cognitive health in mild cognitive impairment: Feasibility and acceptability findings from the TEMPO trial.
Stage: trial early · pubmed · 22-oct-2026

If you are an older adult with mild cognitive impairment and metabolic risk factors, TEMPO reports that an intermittent TRE regimen was feasible and acceptable in a population like yours, not that it improved cognition or prolonged life.

A 16-18-hour time-restricted eating protocol practiced 2-3 days per week is feasible and well accepted among older adults with mild cognitive impairment and metabolic risk factors.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1177/13872877261497622

build build 880 · 2bcef25 · 2026-11-18